{"id":938363,"date":"2026-02-19T13:40:31","date_gmt":"2026-02-19T18:40:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/new-case-study-highlights-ability-of-bioaffinity-technologies-cypath-lung-to-reduce-diagnostic-burden-for-patients-at-risk-for-lung-cancer\/"},"modified":"2026-02-19T13:40:31","modified_gmt":"2026-02-19T18:40:31","slug":"new-case-study-highlights-ability-of-bioaffinity-technologies-cypath-lung-to-reduce-diagnostic-burden-for-patients-at-risk-for-lung-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/new-case-study-highlights-ability-of-bioaffinity-technologies-cypath-lung-to-reduce-diagnostic-burden-for-patients-at-risk-for-lung-cancer\/","title":{"rendered":"New Case Study Highlights Ability of bioAffinity Technologies\u2019 CyPath\u00ae Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer"},"content":{"rendered":"

<\/p>\n

New Case Study Highlights Ability of bioAffinity Technologies\u2019 CyPath\u00ae Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer<\/b><\/p>\n

CyPath\u00ae Lung test supported recommendation for surveillance strategy, rather than subjecting elderly patient to an invasive, risky and costly biopsy procedure<\/i><\/b><\/p>\n

Despite a suspicious nodule during a low-dose CT scan, a repeat scan showed no nodules in the lungs, validating the decision made with CyPath\u00ae Lung\u2019s results<\/i><\/b><\/p>\n

Noninvasive CyPath\u00ae Lung test has shown 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules less than 2 centimeters<\/i><\/b><\/p>\n

SAN ANTONIO, Texas–(BUSINESS WIRE<\/a>)–bioAffinity Technologies, Inc.<\/b><\/a> (Nasdaq: BIAF; BIAFW)<\/b>,a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released a new clinical case study in which its CyPath\u00ae Lung noninvasive diagnostic test for lung cancer helped determine the appropriate treatment for a 79-year-old female with a suspicious lung finding on a low-dose computed tomography (LDCT) scan.<\/p>\n

\nThe patient, a current smoker with a medical history significant for chronic obstructive pulmonary disease (COPD) and coronary heart disease, underwent LDCT screening in June 2025. Imaging revealed a spiculated, or irregularly shaped, nodule about half an inch in size at the bottom of the right lung, near the lining of the lung. Spiculated nodules raise concerns about malignancy due to their uneven, irregular appearance.<\/p>\n

\n\u201cSpiculated findings on CT scans often trigger concern and can lead to invasive procedures, particularly in older high-risk patients,\u201d said Daya Nadarajah, MD, the patient\u2019s pulmonologist. \u201cGiven this patient\u2019s age, smoking history and comorbidities, we were not comfortable proceeding directly to an invasive procedure. CyPath\u00ae Lung gives us objective data to better stratify risk and avoid putting our patients through unnecessary and potentially risky procedures.\u201d<\/p>\n

\nThe CyPath\u00ae Lung test result was negative, indicating an unlikely malignancy in the lung and supporting a conservative management approach that includes annual CT screening. A repeat scan in October 2025 showed that the suspicious finding from the June scan had resolved, and there were no pulmonary nodules in the lungs.<\/p>\n

\n\u201cEvery suspicious finding is concerning. Even when the probability of malignancy is low, the consequences of missing a cancer are significant,\u201d said Gordon Downie, MD, PhD, bioAffinity Technologies Chief Medical Officer. \u201cPhysicians now have a tool in CyPath\u00ae Lung that further refines risk and provides valuable reassurance when deciding whether to monitor or escalate care.\u201d<\/p>\n

Supporting Confident, Noninvasive Management<\/b><\/p>\n

\nBased on the reassuring imaging and negative CyPath\u00ae Lung result, the patient and her care team agreed to continue with serial annual CT scans as follow-up care. In this case, CyPath\u00ae Lung:<\/p>\n